BioSpace News Archive

FibroBiologics, a clinical stage company developing fibroblast-based therapeutic solutions for chronic diseases, announced today the formation of its Board of Directors.

Alginate dressings have the capability to absorb fluid from the wounds and form gels that can provide a dry wound with a moist environment which further reduces bacterial infections, and promotes rapid re-epithelialization and granulation tissue formation.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

The transcranial magnetic stimulator (TMS) market is projected to reach US$ 2,029.71 million by 2028 from US$ 1,122.22 million in 2021; it is expected to register a CAGR of 8.8% from 2021 to 2028.

Rise in the prevalence of infectious diseases, increase in immunization programs across the globe, and surge in R&D activities to develop new vaccine drive the growth of the global vaccine market.

Synedgen, a biotechnology company using glycopolymer chemistry to develop therapeutics that enhance and control signaling in the innate immune system, today announced the initiation of a randomized controlled trial (RCT) to test the safety and effectiveness of SynePure™ Wound Cleanser (SynePure) in combination with Catasyn™ Advanced Technology Hydrogel (Catasyn) for the treatment of superficial partial-thickness burn wounds.

The U.S. Food and Drug Administration (FDA) has approved Nexviazyme® (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilitating muscle disorder that impairs a person’s ability to move and breathe.

Ending the COVID-19 pandemic will require most Americans to be vaccinated. Yet vaccination has become politically polarized, with Republicans being the most consistently hesitant, and the gap in vaccination rates between U.S. counties that voted for Joe Biden and those that voted for Donald Trump continuing to grow.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on August 2, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 15,938 shares of Puma common stock to three new non-executive employees.